Trial intelligence / Profile preview

Larotaxel in metastatic breast cancer

NCT00087958Phase 2Completed

Sponsor
Sanofi
Start
Aug 2004
Primary completion
Feb 2007
Modality
Small Molecules
Countries
15
01

Overview

Phase 2, open-label, single-arm trial of larotaxel in breast cancer, sponsored by Sanofi. Primary endpoint: Objective Response Rate. Started Aug 2004; status: completed.

02

Drugs

larotaxel
03

Conditions

breast cancer

Beyond the preview

Go deeper on NCT00087958.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00087958.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call